Athenex (ATNX) Cut to Buy at BidaskClub

BidaskClub cut shares of Athenex (NASDAQ:ATNX) from a strong-buy rating to a buy rating in a research note issued to investors on Thursday.

Several other analysts have also issued reports on ATNX. Zacks Investment Research raised Athenex from a hold rating to a buy rating and set a $19.00 target price on the stock in a report on Tuesday, April 10th. Needham & Company LLC assumed coverage on Athenex in a report on Tuesday, March 6th. They set a buy rating and a $30.00 target price on the stock. JPMorgan Chase increased their target price on Athenex from $22.20 to $23.00 and gave the stock a neutral rating in a report on Wednesday, January 24th. Finally, Deutsche Bank set a $20.00 target price on Athenex and gave the stock a buy rating in a report on Wednesday, January 17th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Athenex currently has an average rating of Buy and a consensus target price of $26.86.

How to Become a New Pot Stock Millionaire

ATNX opened at $16.30 on Thursday. The firm has a market cap of $1,055.88 and a PE ratio of -7.03. Athenex has a 52-week low of $11.21 and a 52-week high of $20.79. The company has a current ratio of 1.86, a quick ratio of 1.49 and a debt-to-equity ratio of 0.01.

Athenex (NASDAQ:ATNX) last released its earnings results on Monday, March 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.33). The firm had revenue of $14.87 million during the quarter. equities analysts forecast that Athenex will post -1.4 earnings per share for the current year.

In other Athenex news, CEO Johnson Yiu Nam Lau acquired 20,000 shares of Athenex stock in a transaction that occurred on Thursday, February 8th. The shares were acquired at an average cost of $14.40 per share, with a total value of $288,000.00. Following the completion of the purchase, the chief executive officer now directly owns 2,767,922 shares of the company’s stock, valued at approximately $39,858,076.80. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Manson Fok acquired 30,000 shares of Athenex stock in a transaction that occurred on Wednesday, February 7th. The stock was acquired at an average cost of $14.31 per share, for a total transaction of $429,300.00. Following the completion of the purchase, the director now directly owns 1,799,609 shares of the company’s stock, valued at $25,752,404.79. The disclosure for this purchase can be found here. Insiders purchased 89,500 shares of company stock worth $1,287,550 over the last ninety days.

Large investors have recently added to or reduced their stakes in the stock. Private Advisor Group LLC acquired a new stake in Athenex in the fourth quarter valued at about $161,000. California State Teachers Retirement System acquired a new stake in Athenex in the third quarter valued at about $198,000. Deutsche Bank AG boosted its stake in Athenex by 190.8% in the fourth quarter. Deutsche Bank AG now owns 18,511 shares of the company’s stock valued at $293,000 after buying an additional 12,146 shares in the last quarter. Virtus Fund Advisers LLC bought a new position in Athenex in the fourth quarter valued at about $333,000. Finally, Schwab Charles Investment Management Inc. bought a new position in Athenex in the third quarter valued at about $524,000. 5.86% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Athenex (ATNX) Cut to Buy at BidaskClub” was posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.thelincolnianonline.com/2018/04/22/athenex-atnx-cut-to-buy-at-bidaskclub.html.

Athenex Company Profile

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer. Its Orascovery product candidates include Oraxol, an oral dosage form, which is in a Phase III trial in metastatic breast cancer for the treatment of advanced gastric cancer; Oratecan, an anticancer agent that is in a Phase 1 study for the treatment of colorectal, lung, ovarian, cervical, pancreatic, upper gastrointestinal, and brain cancer; Oradoxel, an anticancer agent, which is in a Phase 1 clinical study in the treatment of breast, prostate, gastric, head and neck, and lung cancer; and Oratopo, an anticancer for the treatment of cervical, ovarian ,and lung cancer.

Analyst Recommendations for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply